Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. (Q34471583)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07 (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

phase II clinical trial

0 references

multicenter clinical trial

0 references

chemoradiotherapy

0 references

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

D Helbling

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

O Gautschi

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

H Sun

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

F Bosman

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

B Gloor

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

R Burkhard

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

R Winterhalder

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

A Madlung

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

D Rauch

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

P Saletti

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

L Widmer

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

M Borner

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

D Baertschi

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

P Yan

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

J Benhattar

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

E O Leibundgut

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

S Bougel

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

D Koeberle

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

publication date

8 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

718-725

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23139259%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Chemotherapy with preoperative radiotherapy in rectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Treatment of locally advanced rectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Preoperative versus postoperative chemoradiotherapy for rectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

The epidermal growth factor receptor mediates radioresistance.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Risk factors for anastomotic leakage after resection of rectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS519

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34471583&oldid=1976379357"